Profile data is unavailable for this security.
About the company
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
- Revenue in SEK (TTM)199.81m
- Net income in SEK-304.77m
- Incorporated2008
- Employees65.00
- LocationXbrane Biopharma ABRetzius Vag 8SOLNA 171 65SwedenSWE
- Phone+46 855905600
- Websitehttps://xbrane.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guard Therapeutics Intrntnl AB (publ) | 0.00 | -87.20m | 248.36m | 6.00 | -- | 3.85 | -- | -- | -8.16 | -8.16 | 0.00 | 5.25 | 0.00 | -- | -- | -- | -96.71 | -69.56 | -117.53 | -78.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.4289 | -- | -- | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -52.45m | 254.76m | 4.00 | -- | 10.16 | -- | -- | -0.1734 | -0.1734 | 0.00 | 0.0471 | 0.00 | -- | -- | 0.00 | -235.29 | -125.42 | -407.84 | -151.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.17 | -- | -- | -- |
| Ascelia Pharma AB | 0.00 | -62.30m | 256.05m | 13.00 | -- | 2.41 | -- | -- | -1.12 | -1.12 | 0.00 | 1.11 | 0.00 | -- | -- | 0.00 | -46.53 | -- | -56.96 | -- | -- | -- | -- | -- | -- | -10.21 | 0.1983 | -- | -- | -- | 16.72 | -- | -- | -- |
| Herantis Pharma Oyj | 0.00 | -7.12m | 288.31m | 11.00 | -- | 12.16 | 11.95 | -- | -0.0146 | -0.0146 | 0.00 | 0.1012 | 0.00 | -- | -- | 0.00 | -13.93 | -80.46 | -27.32 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0145 | -- | -- | -- | 103.00 | -- | -- | -- |
| Lytix Biopharma AS | 14.40m | -76.21m | 295.77m | 10.00 | -- | 5.01 | -- | 20.54 | -1.83 | -1.83 | 0.3454 | 1.19 | 0.1563 | -- | 1.42 | 1,444,300.00 | -82.70 | -56.91 | -103.61 | -65.83 | -- | -- | -529.29 | -771.78 | -- | -- | 0.0482 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
| Medivir AB | 6.93m | -116.92m | 296.12m | 10.00 | -- | 2.09 | -- | 42.71 | -1.42 | -1.42 | 0.0735 | 1.26 | 0.0365 | -- | 1.31 | 693,300.00 | -61.49 | -28.91 | -81.28 | -34.77 | -1,300.04 | -467.42 | -1,686.46 | -675.96 | -- | -- | 0.0628 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| Active Biotech AB publ | 0.00 | -41.60m | 303.90m | 8.00 | -- | 160.26 | -- | -- | -0.0644 | -0.0644 | 0.00 | 0.0018 | 0.00 | -- | -- | -- | -284.93 | -57.97 | -1,027.16 | -97.83 | -- | -- | -- | -1,454.61 | -- | -- | 0.5758 | -- | -- | -- | 21.54 | -- | -- | -- |
| Xbrane Biopharma AB | 199.81m | -304.77m | 310.49m | 65.00 | -- | 1.19 | -- | 1.55 | -0.7304 | -0.9784 | 0.2266 | 0.1701 | 0.2309 | 0.4396 | 5.01 | 2,148,473.00 | -35.22 | -40.98 | -70.65 | -67.24 | 61.87 | -- | -152.53 | -364.40 | 0.8986 | -8.52 | 0.3957 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Bergenbio ASA | 519.42k | -151.83m | 312.30m | 15.00 | -- | 2.04 | -- | 601.24 | -4.93 | -4.93 | 0.0162 | 3.92 | 0.0027 | -- | 0.0384 | 20,840.00 | -79.58 | -66.15 | -96.80 | -78.74 | -- | -- | -29,229.94 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Oncopeptides AB | 27.07m | -282.39m | 314.01m | 79.00 | -- | 2.32 | -- | 11.60 | -1.94 | -1.94 | 0.1763 | 0.6421 | 0.0882 | 0.8441 | 0.6929 | 474,929.80 | -91.96 | -141.28 | -107.34 | -200.49 | 89.97 | -- | -1,043.16 | -2,689.06 | 6.16 | -199.53 | 0.5030 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Saniona AB | 24.88m | -81.81m | 315.52m | 22.00 | -- | 45.24 | -- | 12.68 | -0.9821 | -0.9821 | 0.2822 | 0.0623 | 0.2386 | -- | 6.23 | 1,081,652.00 | -78.47 | -59.16 | -168.78 | -70.15 | -92.01 | -970.05 | -328.83 | -1,483.55 | -- | -3.03 | 0.8668 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
| Alzinova AB | 300.00k | -18.72m | 329.91m | 5.00 | -- | 2.53 | -- | 1,099.71 | -0.3144 | -0.3144 | 0.0048 | 1.46 | 0.0023 | -- | 0.4478 | 60,000.00 | -14.06 | -10.77 | -14.94 | -11.27 | -2,642.00 | -- | -6,240.33 | -18,447.90 | -- | -172.34 | 0.0061 | -- | -- | -- | -25.92 | -- | 15.81 | -- |
| Cantargia AB | 0.00 | -193.53m | 335.78m | 21.00 | -- | 6.86 | -- | -- | -1.07 | -1.07 | 0.00 | 0.2664 | 0.00 | -- | -- | 0.00 | -121.74 | -55.08 | -165.80 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -26.36m | 362.18m | 3.00 | -- | 13.00 | -- | -- | -0.4803 | -0.4803 | 0.00 | 0.5256 | 0.00 | -- | -- | 0.00 | -65.39 | -68.27 | -73.28 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -41.82m | 362.85m | 7.00 | -- | 7.39 | -- | -- | -0.2756 | -0.2756 | 0.00 | 0.3842 | 0.00 | -- | -- | 0.00 | -86.17 | -80.47 | -92.51 | -97.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -104.57 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -154.57m | 370.02m | 6.00 | -- | 2.19 | -- | -- | -4.25 | -4.25 | 0.00 | 4.10 | 0.00 | -- | -- | 0.00 | -62.70 | -125.17 | -70.31 | -151.70 | -- | -- | -- | -- | -- | -199.31 | 0.0084 | -- | -- | -- | -117.54 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Xbrane Biopharma AB's reporting currency: Swedish Krona SEK
6.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Oct 2024 | 51.94m | 3.40% |
| Swedbank Robur Fonder ABas of 29 May 2024 | 15.20m | 0.99% |
| Teknik Innovation Norden Fonder ABas of 31 Dec 2022 | 13.70m | 0.90% |
| SEB Investment Management ABas of 31 Oct 2024 | 7.60m | 0.50% |
| FCG Fonder ABas of 31 Oct 2024 | 5.19m | 0.34% |
| Storebrand Asset Management ASas of 30 Sep 2024 | 1.23m | 0.08% |
| Skandia Investment Management ABas of 30 Sep 2024 | 1.13m | 0.07% |
| Danske Bank A/S (Investment Management)as of 31 Oct 2024 | 66.66k | 0.00% |
| Rockbridge TFIas of 31 Dec 2023 | 17.64k | 0.00% |
More ▼
Data from 31 Dec 2022 - 31 Oct 2024Source: FactSet Research Systems Inc.
